Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb

Published 08/08/2022, 05:15 PM
Updated 08/08/2022, 05:17 PM
© Reuters.  After-Hours Movers: Novavax Sinks Over 30%, GoodRx and Lemonade Climb

GoodRx Holdings, Inc. (GDRX) +34%; Revenue for the quarter came in at $191.8 million versus the consensus estimate of $185.36 million.

Lemonade (LMND) +13%; reported Q2 EPS of ($1.10), $0.23 better than the analyst estimate of ($1.33). Revenue for the quarter came in at $50 million versus the consensus estimate of $47.56 million.GUIDANCE: Lemonade sees Q3 2022 revenue of $63-65 million, versus the consensus of $56.98 million. Lemonade sees FY2022 revenue of $236-239 million, versus the consensus of $214.67 million.

Bed Bath & Beyond (NASDAQ:BBBY) +9%; extends earlier gain after meme stocks bid higher.

CorMedix (CRMD) -58%; today announced updates related to the FDA review of the DefenCath New Drug Application (NDA) as well as other manufacturing and commercial updates. A second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies recently conveyed to the contract manufacturing organization (CMO) and the supplier of the active pharmaceutical ingredient (API) heparin during inspections are resolved to the satisfaction of FDA.

Novavax (NASDAQ:NVAX) -32%; Novavax (NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion. GUIDANCE: Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.

TaskUs, Inc. (TASK) -16%; reported Q2 EPS of $0.38, $0.05 better than the analyst estimate of $0.33. Revenue for the quarter came in at $246.5 million versus the consensus estimate of $242.11 million. GUIDANCE: TaskUs, Inc. sees Q3 2022 revenue of $224-226 million, versus the consensus of $244 million. TaskUs, Inc. sees FY2022 revenue of $930-950 million, versus the consensus of $992 million.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

CarGurus (NASDAQ:CARG) -15%; reported Q2 EPS of $0.32, $0.01 better than the analyst estimate of $0.31. Revenue for the quarter came in at $511.2 million versus the consensus estimate of $507.32 million. GUIDANCE: CarGurus sees Q3 EPS of $0.25-$0.28, versus the consensus of $0.33. CarGurus sees Q3 revenue of $460-490 million, versus the consensus of $554.6 million.

3D Systems (NYSE:DDD) -13% ; reported Q2 EPS of ($0.07), $0.07 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 million versus the consensus estimate of $146.8 million. GUIDANCE: 3D Systems sees 2022 revenue of $530-570 million, versus the consensus of $598 million.

Allbirds, Inc. (BIRD) -13%; reported Q2 EPS of ($0.12), $0.04 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $78.2 million versus the consensus estimate of $77.8 million. GUIDANCE: Allbirds, Inc. sees FY2022 revenue of $305-315 million, versus the consensus of $339.6 million.

Trex (TREX) -12%; reported Q2 EPS of $0.79, $0.12 better than the analyst estimate of $0.67. Revenue for the quarter came in at $386 million versus the consensus estimate of $381.1 million. GUIDANCE: Trex sees Q3 2022 revenue of $185-195 million, versus the consensus of $354.82 million. Trex sees FY2022 revenue of $1.09-1.11 billion, versus the consensus of $1.38 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.